INTRODUCTION {#s1}
============

Tumor necrosis factor-alpha (*TNF-α*) gene, located on chromosome 6p21.231, consists of four exons \[[@R1], [@R2]\]. TNF-α protein, encoded by *TNF-α* gene, is associated with cellular differentiation, proliferation, apoptosis, inflammatory responses, insulin resistance, and tumorigenesis \[[@R2]--[@R4]\]. Several single nucleotide polymorphisms (SNPs), including rs1800629 (−308 G/A) and rs361525 (−238 G/A), have been identified in the promoter region of *TNF-α* gene \[[@R2]\].

The role of *TNF-α* gene mutations in the risk of squamous cell carcinoma (SCC) remains inconclusive. For instance, the rs1800629 polymorphism of *TNF-α* gene has been linked to the risk of esophageal SCC in northern Indian patients \[[@R5]\], but not in Kazakh patients \[[@R6]\]. *TNF-α* rs1800629 polymorphism has been associated with the risks of oral SCC in Taiwan \[[@R7]\], but not in northern Indian population, which has been linked with rs361525 polymorphism \[[@R8]\]. There was also no association between the rs1800629 polymorphism and lung SCC risk in the German population \[[@R9]\].

Skin cancer comprises cutaneous melanoma, skin SCC (SSCC), and skin basal cell carcinoma (SBCC) \[[@R10]\]. Allelic variants of *TNF-α* gene have been reported to contribute to the risk of skin cancer in certain populations. For example, the study by Rizzato et al. has indicated that *TNF-α* rs1800629 might affect the SBCC risk in Caucasian population \[[@R11]\]. The A allele or GA genotype of *TNF-α* gene rs1800629 polymorphism was also reported to influence the course of BCC in Polish population \[[@R12]\]. However, the role of *TNF-α* polymorphisms in skin cancer is still inconclusive. For example, Skov et al. reported that TNF-α release, but not rs1800629 polymorphism, was linked to the SBCC risk in Caucasian population \[[@R13]\]. To our knowledge, no meta-analysis has been previously performed to assess the link between *TNF-α* polymorphisms and the risk of skin cancer.

Therefore, in this study, we carried out a comprehensive systematic review and meta-analysis to determine the association of *TNF-α* polymorphisms and the risk of skin cancer and different SCC diseases.

RESULTS {#s2}
=======

Characteristics of studies included in meta-analysis {#s2_1}
----------------------------------------------------

Six databases, including PUBMED, Web of Science (WOS), EMBASE, WANFANG, CNKI, and SCOPUS, were electronically searched on January 17^th^, 2017 to identify the eligible studies. The search details are shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Flowchart of the search strategy and article selection for meta-analysis is shown in Figure [1](#F1){ref-type="fig"}. Briefly, 985 related articles were obtained from the above databases. After 241 duplicated articles were removed, 699 articles were excluded by screening the title and abstract. The eligibility of 45 full-text articles was then assessed, and 25 articles were excluded. The results are shown in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}. Finally, 20 eligible articles with 4865 cases and 6329 controls were included for quantitative synthesis \[[@R1], [@R5]--[@R9], [@R11]--[@R24]\]. All selected articles met the inclusion and exclusion criteria. We used the Newcastle-Ottawa Scale (NOS) to assess the quality of the studies. As shown in [Supplementary Table 3](#SD2){ref-type="supplementary-material"}, the NOS scores of all studies were equal to or greater than 7, indicating a high quality. After covariate adjustment in logistic regression, the characteristics and genotype distributions of included studies are shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

![The selection process of the meta-analysis](oncotarget-08-53873-g001){#F1}

###### Characteristics of studies included in meta-analysis

  First author\[Ref\]       Year   Country     Ethnicity   Number   Source of controls   Age (mean value)   Genotyping assay   Gender (male %)                                       
  ------------------------- ------ ----------- ----------- -------- -------------------- ------------------ ------------------ ----------------- ----------------------- ----------- --------
  Cui \[[@R6]\]             2015   China       Asian       212      200                  Population         52.5               54.4              PCR-RFLP                59.7%       51.8%
  Flego \[[@R14]\]          2009   Croatia     Caucasian   113      230                  Population         NA                 NA                PCR-RFLP                NA          NA
  Gu \[[@R15]\]             2009   USA         Caucasian   212      211                  Population         NA                 NA                ARMS-PCR                NA          NA
  Gupta \[[@R1]\]           2008   India       Asian       94       133                  Population         50.7               NA                PCR-RFLP                80.9%       NA
  Huang \[[@R19]\]          2005   China       Asian       65       65                   Population         65.0               55.0              PCR-RFLP                81.5%       77.0%
  Kietthubthew \[[@R24]\]   2010   Thailand    Asian       97       152                  Population         67.5               69.7              Taqman PCR              73.8%       55.4%
  Kostic \[[@R17]\]         2013   Serbia      Caucasian   50^\#^   60                   Population         69.0^\#^           NA                PCR-RFLP                70.0%^\#^   NA
                                                           50^&^    60                   Population         73.0^&^            NA                PCR-RFLP                40.0%^&^    NA
  Liu \[[@R7]\]             2005   China       Asian       192      146                  Population         54.1               52.0              PCR-RFLP                90.1%       89.0%
  Oh \[[@R23]\]             2010   USA         Caucasian   75       839                  Population         NA                 NA                SNPlex assay            NA          NA
  Rizzato \[[@R11]\]        2011   Mixed       Caucasian   506      515                  Hospital           67.0               61.0              KASPar SNP genotyping   44.8%       51.4%
  Seifart \[[@R9]\]         2005   Germany     Caucasian   40       242                  Population         65.4               37.9              PCR-RFLP                NA          55.1%
  Shih \[[@R20]\]           2006   China       Asian       83       205                  Population         NA                 62.8              PCR-RFLP+ sequencing    NA          66.3%
  Singh \[[@R8]\]           2015   India       Asian       272      185                  Population         47.7               43.1              PCR-RFLP                80.5%       76.8%
  Skov \[[@R13]\]           2003   Denmark     Caucasian   191      107                  Population         65.9               64.6              PCR-RFLP                59.2%       53.3%
  Sobjanek \[[@R12]\]       2015   Poland      Caucasian   176      261                  Population         68.9               NA                ARMS-PCR                46.6%       NA
  Umar \[[@R5]\]            2013   India       Asian       290      311                  Population         57.0               55.0              ARMS-PCR                72.8%       71.1%
  Welsh \[[@R16]\]          2011   USA         Caucasian   894^&^   816                  Population         58.7^&^            61.3              Taqman PCR              56.0%^&^    59.9%
                                                           681\*    816                  Population         64.1\*             61.3              Taqman PCR              63.5%\*     59.9%
  Whiteman \[[@R18]\]       2010   Australia   Caucasian   207      1293                 Population         NA                 NA                Sequenom iPLEX          58.0%       66.0%
  Yang \[[@R21]\]           2011   China       Asian       205      198                  Population         49.3               48.9              Taqman PCR              100.0%      100.0%
  Zhang \[[@R22]\]          2011   China       Asian       160      160                  NA                 NA                 NA                PCR-SSP                 NA          NA

Ref: reference; \#: OSCC group; &: SBCC group; \*: SSCC group; NA: not available; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; ARMS-PCR: amplification refractory mutation system-polymerase chain reaction; Taqman PCR: Taqman polymerase chain reaction; PCR-SSP: Polymerase chain reaction-sequence specific primer.

###### The genotype data of studies included in meta-analysis

  Group             SNP         First author \[Ref\]      Year   Case   Disease   Control   HWE                                               
  ----------------- ----------- ------------------------- ------ ------ --------- --------- ----- ---------- ------ ----- ------- ---- ------ --------
  **SSC**           rs1800629   Flego \[[@R14]\]          2009   113    79        30        4     LSCC       230    171   53      6    0.59   0.44
                                Huang \[[@R19]\]          2005   65     64        1         0     LSCC       65     55    10      0    0.45   0.50
                                Oh \[[@R23]\]             2010   75     56        18        1     LSCC       839    632   194     13   0.19   0.67
                                Seifart \[[@R9]\]         2005   40     24        15        1     LSCC       242    171   67      4    0.79   0.37
                                Shih \[[@R20]\]           2006   83     50        25        8     LSCC       205    169   34      2    0.04   0.84
                                Gupta \[[@R1]\]           2008   94     61        23        10    OSCC       133    114   19      0    0.79   0.38
                                Kietthubthew \[[@R24]\]   2010   97     83        14^&^     \-    OSCC       152    133   19^&^   \-   NA     \>0.05
                                Kostic \[[@R17]\]         2013   50     35        14        1     OSCC       60     39    21      0    2.70   0.10
                                Liu \[[@R7]\]             2005   192    175       16        1     OSCC       146    120   24      2    0.39   0.53
                                Singh \[[@R8]\]           2015   272    235       35        2     OSCC       185    164   20      1    0.21   0.65
                                Cui \[[@R6]\]             2015   212    150       57        5     ESCC       200    140   58      2    2.29   0.13
                                Umar \[[@R5]\]            2013   290    227       62        1     ESCC       311    268   42      1    0.23   0.63
                                Whiteman \[[@R18]\]       2010   207    128       71        8     ESCC       1293   842   403     48   0.00   0.98
                                Zhang \[[@R22]\]          2011   160    135       23        2     ESCC       160    140   18      2    2.36   0.12
                                Yang \[[@R21]\]           2011   205    180       23        2     OPSCC      198    155   43      0    2.94   0.09
                                Welsh \[[@R16]\]          2011   681    476       188       17    SSCC       816    571   223     22   0.00   0.97
  **SSC**           rs361525    Kietthubthew \[[@R24]\]   2010   97     92        5^&^      \-    OSCC       152    141   11^&^   \-   NA     \>0.05
                                Liu \[[@R7]\]             2005   192    188       4         0     OSCC       146    136   10      0    0.18   0.67
                                Singh \[[@R8]\]           2015   272    252       20        0     OSCC       185    180   5       0    0.03   0.85
                                Flego \[[@R14]\]          2009   113    108       5         0     LSCC       230    214   16      0    0.30   0.58
                                Shih \[[@R20]\]           2006   83     75        8         0     LSCC       205    161   44      0    2.96   0.09
                                Yang \[[@R21]\]           2011   205    200       5         0     OPSCC      198    187   11      0    0.16   0.69
  **skin cancer**   rs1800629   Gu \[[@R15]\]             2009   212    156       46        10    melanoma   211    140   61      10   0.98   0.32
                                Kostic \[[@R17]\]         2013   50     29        21        0     SBCC       60     39    21      0    2.70   0.10
                                Rizzato \[[@R11]\]        2011   506    358       128       20    SBCC       515    390   117     8    0.05   0.82
                                Skov \[[@R13]\]           2003   191    133       49        9     SBCC       107    68    37      2    1.45   0.23
                                Sobjanek \[[@R12]\]       2015   176    134       41        1     SBCC       261    178   80      3    3.38   0.07
                                Welsh \[[@R16]\]          2011   894    612       265       17    SBCC       816    571   223     22   0.00   0.97
                                                                 681    476       188       17    SSCC       816    571   223     22   0.00   0.97

Ref: reference; SCC: squamous cell carcinoma; SNP: single nucleotide polymorphisms; &: the number of GA+AA; NA: not available; LSCC: lung squamous cell carcinoma; OSCC: oral squamous cell carcinoma; ESCC: esophageal squamous cell carcinoma; OPSCC: oral and pharyngeal squamous cell carcinoma; SSCC: skin squamous cell carcinoma; SBCC: skin basal cell carcinomas; HWE: Hardy-Weinberg equilibrium.

Association between *TNF-α* rs1800629 polymorphism and the risk of SCC {#s2_2}
----------------------------------------------------------------------

Meta-analysis of 16 studies \[[@R1], [@R5]--[@R9], [@R14], [@R16]--[@R24]\] comprising 2836 cases and 5235 controls was performed to analyze the association between *TNF-α* rs1800629 polymorphism and the risk of SCC under allele model (A vs G), homozygote model (AA vs GG), heterozygote model (GA vs GG), dominant model (GA+AA vs GG), recessive model (AA vs GG+GA), and carrier model (carrier A vs G). Pooled analysis data are shown in Table [3](#T3){ref-type="table"}. Compared with the control group, no significant overall SCC risk was observed in the case group under A vs G model (OR=1.18, 95% CI=0.92∼1.51, *P~association~*=0.192), GA vs GG model (OR=1.10, 95% CI=0.87∼1.39, *P~association~*=0.439), GA+AA vs GG (OR=1.15, 95% CI=0.90∼1.47, *P~association~*=0.255), or carrier A vs G model (OR=1.12, 95% CI=0.91∼1.39, *P~association~*=0.287). However, an increased overall SCC risk was observed in AA vs GG model (OR=1.62, 95% CI=1.15∼2.29, *P~association~*=0.006) and AA vs GG+GA model (OR=1.56, 95% CI=1.10∼2.20, *P~association~*=0.012).

###### Pooled analysis for the association between *TNF-α* rs1800629 polymorphism and the risk of SCC

  Comparison           Subgroup    Test of association   Number                                        
  -------------------- ----------- --------------------- ------------ ------ ------------- ---- ------ ------
  **A vs G**           overall     1.18                  0.92∼1.51    1.30   0.192         15   2739   5083
                       Asian       1.18                  0.73∼1.92    0.67   0.501         9    1573   1603
                       Caucasian   1.07                  0.93∼1.22    0.94   0.349         6    1166   3480
                       ESCC        1.19                  0.99∼1.44    1.84   0.066         4    869    1964
                       LSCC        1.39                  0.72∼2.36    0.87   0.385         5    376    1581
                       OSCC        1.19                  0.49∼2.88    0.39   0.697         4    608    524
  **AA vs GG**         overall     1.62                  1.15∼2.29    2.73   **0.006**     14   2674   5018
                       Asian       3.67                  1.89∼7.16    3.82   **\<0.001**   8    1508   1538
                       Caucasian   1.08                  0.70∼1.66    0.33   0.743         6    1166   3480
                       ESCC        1.24                  0.66∼2.32    0.68   0.497         4    869    1964
                       LSCC        2.72                  1.32∼5.61    2.72   **0.007**     4    311    1516
                       OSCC        3.91                  1.38∼11.05   2.57   **0.010**     4    608    524
  **GA vs GG**         overall     1.10                  0.87∼1.39    0.77   0.439         15   2739   5083
                       Asian       1.05                  0.67∼1.64    0.20   0.839         9    1573   1603
                       Caucasian   1.08                  0.92∼1.27    0.97   0.334         6    1166   3480
                       ESCC        1.23                  0.95∼1.61    1.55   0.120         4    869    1964
                       LSCC        1.27                  0.74∼2.18    0.85   0.393         5    376    1581
                       OSCC        0.99                  0.51∼1.95    0.02   0.986         4    608    524
  **GA+AA vs GG**      overall     1.15                  0.90∼1.47    1.14   0.255         16   2836   5235
                       Asian       1.14                  0.73∼1.77    0.56   0.577         10   1670   1755
                       Caucasian   1.08                  0.93∼1.26    0.99   0.324         6    1166   3480
                       ESCC        1.24                  0.97∼1.57    1.73   0.084         4    869    1964
                       LSCC        1.31                  0.71∼2.40    0.86   0.389         5    376    1581
                       OSCC        1.12                  0.58∼2.15    0.33   0.738         5    705    676
  **AA vs GG+GA**      overall     1.56                  1.10∼2.20    2.53   **0.012**     14   2674   5018
                       Asian       3.52                  1.80∼6.88    3.68   **\<0.001**   8    1508   1538
                       Caucasian   1.05                  0.68∼1.62    0.22   0.829         6    1166   3480
                       ESCC        1.19                  0.64∼2.22    0.56   0.577         4    869    1964
                       LSCC        2.48                  1.20∼5.12    2.45   **0.014**     4    311    1516
                       OSCC        3.84                  1.34∼11.01   2.50   **0.012**     4    608    524
  **carrier A vs G**   overall     1.12                  0.91∼1.39    1.06   0.287         15   2739   5083
                       Asian       1.12                  0.74∼1.69    0.52   0.604         9    1573   1603
                       Caucasian   1.06                  0.91∼1.22    0.73   0.468         6    1166   3480
                       ESCC        1.17                  0.96∼1.42    1.59   0.111         4    869    1964
                       LSCC        1.24                  0.75∼2.07    0.84   0.402         5    376    1581
                       OSCC        1.10                  0.54∼2.24    0.27   0.789         4    608    524

ESCC: esophageal squamous cell carcinoma; LSCC: lung squamous cell carcinoma; OSCC: oral squamous cell carcinoma; Ors: odd ratios; CIs: confidence intervals.

There are several types of SCC, including skin SCC (SSCC), esophageal SCC (ESCC), oral SCC (OSCC), and lung SCC (LSCC). We performed subgroup analyses of the above SCC types and different ethnicities under all models. As shown in Table [3](#T3){ref-type="table"} and Figure [2A](#F2){ref-type="fig"}, an increased overall SCC risk was observed in the Asian population under AA vs GG model (OR=3.67, 95% CI=1.89∼7.16, *P~association~*\<0.001). The increased risk of LSCC (OR=2.72, 95% CI=1.32∼5.61, *P~association~*=0.007) and OSCC (OR=3.91, 95% CI=1.38∼11.05, *P~association~*=0.010) was also observed (Table [3](#T3){ref-type="table"} and Figure [2B](#F2){ref-type="fig"}). Similar results were observed for the AA vs GG+GA model (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). No significant difference was found under other genetic models (all *P~association~*\>0.05). These data indicate that the AA genotype of *TNF-α* rs1800629 polymorphism correlates with the higher susceptibility towards SCC.

![Forest plot for the association between *TNF-α* rs1800629 polymorphism and the risk of SCC under AA vs GG model\
**(A)** Subgroup analyses based on ethnicity; **(B)** Subgroup analyses based on disease type.](oncotarget-08-53873-g002){#F2}

![Forest plot for the association between *TNF-α* rs1800629 polymorphism and the risk of SCC under AA vs GG+GA model\
**(A)** Subgroup analyses based on ethnicity; **(B)** Subgroup analyses based on disease type.](oncotarget-08-53873-g003){#F3}

Association between *TNF-α* rs361525 polymorphism and the risk of SCC {#s2_3}
---------------------------------------------------------------------

Meta-analysis of the relationship between *TNF-α* rs361525 polymorphism and susceptibility to SCC was also performed. Six studies comprising 962 cases and 1116 controls were analyzed \[[@R7], [@R8], [@R14], [@R20], [@R21], [@R24]\]. Data of pooled analysis indicated that there was no significant difference for overall SCC risk under all genetic models (Table [4](#T4){ref-type="table"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}; all *P~association~*\>0.05). Subgroup analysis (Table [4](#T4){ref-type="table"}) indicated a decreased LSCC risk under A vs G model (OR=0.49, 95% CI=0.26∼0.90, *P~association~*=0.023), GA vs GG model (OR=0.46, 95% CI=0.25∼0.87, *P~association~*=0.018); GA+AA vs GG (OR=0.46, 95% CI=0.25∼0.87, *P~association~*=0.018), and carrier A vs G (OR=0.51, 95% CI=0.27∼0.96, *P~association~*=0.037). However, only two case-control studies comprising 196 cases and 435 controls were included in the LSCC subgroup \[[@R14], [@R20]\]. No significant difference was found for other comparisons (all *P~association~*\>0.05). These data indicate that *TNF-α* rs361525 polymorphism does not contribute to the risk of SCC.

###### Pooled analysis for the association between *TNF-α* rs361525 polymorphism and the risk of SCC

  Comparison           Subgroup   Test of association   Number                                   
  -------------------- ---------- --------------------- ----------- ------ ----------- --- ----- ------
  **A vs G**           overall    0.63                  0.29∼1.35   1.19   0.235       5   865   964
                       Asian      0.63                  0.24∼1.68   0.93   0.354       4   752   734
                       LSCC       0.49                  0.26∼0.90   2.28   **0.023**   2   196   435
                       OSCC       0.93                  0.10∼8.36   0.06   0.949       2   464   331
  **GA vs GG**         overall    0.62                  0.28∼1.36   1.20   0.231       5   865   964
                       Asian      0.61                  0.22∼1.70   0.94   0.348       4   752   734
                       LSCC       0.46                  0.25∼0.87   2.38   **0.018**   2   196   435
                       OSCC       0.93                  0.10∼8.78   0.06   0.949       2   464   331
  **GA+AA vs GG**      overall    0.93                  0.10∼8.78   1.39   0.165       6   962   1116
                       Asian      0.63                  0.28∼1.41   1.13   0.259       5   849   886
                       LSCC       0.46                  0.25∼0.87   2.38   **0.018**   2   196   435
                       OSCC       0.86                  0.23∼3.22   0.23   0.818       3   561   483
  **carrier A vs G**   overall    0.64                  0.31∼1.35   1.17   0.243       5   865   964
                       Asian      0.64                  0.25∼1.67   0.91   0.364       4   752   734
                       LSCC       0.51                  0.27∼0.96   2.09   **0.037**   2   196   435
                       OSCC       0.93                  0.11∼7.98   0.06   0.948       2   464   331

LSCC: lung squamous cell carcinoma; OSCC: oral squamous cell carcinoma; Ors: odd ratios; CIs: confidence intervals.

Association between *TNF-α* rs1800629 polymorphism and the risk of skin cancer {#s2_4}
------------------------------------------------------------------------------

We then performed meta-analysis of the relationship between *TNF-α* rs1800629 and the risk of skin cancer, including SSCC, SBCC, and melanoma. Seven studies comprising 2710 cases and 2786 controls were included \[[@R11]--[@R13], [@R15]--[@R17]\]. Data of pooled analysis indicated no significant difference under all genetic models (all *P~association~*\>0.05, Table [5](#T5){ref-type="table"} and [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Subgroup analysis (based PB and SBCC) also showed no significant difference (Table [5](#T5){ref-type="table"}). However, only one case-control study was included in the subgroup analysis of melanoma \[[@R15]\] and SSCC \[[@R16]\] (Table [5](#T5){ref-type="table"}). These data suggest that *TNF-α* rs1800629 polymorphism does not have a significant correlation with the risk of skin cancer.

###### Pooled analysis for the association between *TNF-α* rs1800629 polymorphism and the risk of skin cancer

  Comparison           Subgroup    Test of association   Number                                
  -------------------- ----------- --------------------- ----------- ------ ------- --- ------ ------
  **A vs G**           overall     1.01                  0.91∼1.12   0.24   0.814   7   2710   2786
                       Caucasian   1.01                  0.91∼1.12   0.24   0.814   7   2710   2786
                       PB          0.95                  0.85∼1.07   0.82   0.413   6   2204   2271
                       SBCC        1.05                  0.93∼1.20   0.82   0.411   5   1817   1759
                       melanoma    0.78                  0.54∼1.11   1.39   0.164   1   212    211
                       SSCC        1.00                  0.82∼1.21   0.04   0.964   1   681    816
  **AA vs GG**         overall     1.09                  0.78∼1.54   0.52   0.603   6   2660   2726
                       Caucasian   1.09                  0.78∼1.54   0.52   0.603   6   2660   2726
                       PB          0.88                  0.60∼1.29   0.65   0.513   5   2154   2211
                       SBCC        1.24                  0.79∼1.95   0.95   0.340   4   1767   1699
                       melanoma    0.90                  0.36∼2.22   0.23   0.815   1   212    211
                       SSCC        0.93                  0.49∼1.77   0.23   0.818   1   681    816
  **GA vs GG**         overall     0.99                  0.88∼1.12   0.08   0.933   7   2710   2786
                       Caucasian   0.99                  0.88∼1.12   0.08   0.933   7   2710   2786
                       PB          0.96                  0.84∼1.09   0.64   0.524   6   2204   2271
                       SBCC        1.03                  0.89∼1.20   0.41   0.680   5   1817   1759
                       melanoma    0.68                  0.43∼1.06   1.72   0.086   1   212    211
                       SSCC        1.01                  0.80∼1.27   0.10   0.923   1   681    816
  **GA+AA vs GG**      overall     1.00                  0.89∼1.13   0.07   0.620   7   2710   2786
                       Caucasian   1.00                  0.89∼1.13   0.07   0.620   6   2710   2786
                       PB          0.95                  0.84∼1.08   0.75   0.453   5   2204   2271
                       SBCC        1.05                  0.91∼1.21   0.63   0.527   1   1817   1759
                       melanoma    0.71                  0.47∼1.08   1.62   0.105   1   212    211
                       SSCC        1.00                  0.80∼1.25   0.03   0.974   7   681    816
  **AA vs GG+GA**      overall     1.10                  0.79∼1.55   0.57   0.569   6   2660   2726
                       Caucasian   1.10                  0.79∼1.55   0.57   0.569   6   2660   2726
                       PB          0.90                  0.62∼1.31   0.54   0.587   5   2154   2211
                       SBCC        1.23                  0.79∼1.93   0.92   0.359   4   1767   1699
                       melanoma    1.00                  0.41∼2.44   0.01   0.991   1   212    211
                       SSCC        0.92                  0.49∼1.75   0.24   0.809   1   681    816
  **carrier A vs G**   overall     1.01                  0.90∼1.12   0.10   0.920   7   2710   2786
                       Caucasian   1.01                  0.90∼1.12   0.10   0.920   7   2710   2786
                       PB          0.96                  0.85∼1.09   0.59   0.553   6   2204   2271
                       SBCC        1.01                  0.90∼1.19   0.53   0.595   5   1817   1759
                       melanoma    0.78                  0.53∼1.17   1.18   0.236   1   212    211
                       SSCC        1.00                  0.81∼1.24   0.01   0.996   1   681    816

SBCC: skin basal cell carcinomas; SSCC: skin squamous cell carcinoma, Ors: odd ratios; CIs: confidence intervals.

Heterogeneity, publication bias and sensitivity analysis {#s2_5}
--------------------------------------------------------

Regarding the rs1800629 polymorphism and SCC risk, A vs G (I^2^ value of 77.5 % and *P*~heterogeneity~ \<0.001), GA vs GG (I^2^=66.3 % and *P*~heterogeneity~ \<0.001), GA+AA vs GG (I^2^=71.4 % and *P*~heterogeneity~ \<0.001) and carrier A vs G (I^2^ =64.0 % and *P*~heterogeneity~ \<0.001) data indicated a high degree of heterogeneity among the studies (Table [6](#T6){ref-type="table"}). Thus, random-effect model was applied. In addition, fixed model was used in AA vs GG (I^2^=30.0 % and *P*~heterogeneity~=0.137) and AA vs GG+GA contrast (I^2^ =23.2 % and *P*~heterogeneity~ =0.203, Table [6](#T6){ref-type="table"}).

###### The analysis of heterogeneity and publication bias

  Group             SNP         Comparison       Heterogeneity   Model     Begg\'s test   Egger\'s test                   
  ----------------- ----------- ---------------- --------------- --------- -------------- --------------- ------- ------- -------
  **SSC**           rs1800629   A vs G           77.5%           \<0.001   Random         0.49            0.621   0.07    0.942
                                AA vs GG         30.0%           0.137     Fixed          1.20            0.228   1.67    0.120
                                GA vs GG         66.3%           \<0.001   Random         0.00            1.000   −0.42   0.683
                                GA+AA vs GG      71.4%           \<0.001   Random         −0.05           1.000   −0.12   0.903
                                AA vs GG+GA      23.2%           0.203     Fixed          1.20            0.228   1.75    0.105
                                carrier A vs G   64.0 %          \<0.001   Random         0.00            1.000   −0.17   0.864
  **SSC**           rs361525    A vs G           66.2%           0.019     Random         0.73            0.462   0.05    0.962
                                GA vs GG         67.7%           0.015     Random         0.73            0.462   0.05    0.962
                                GA+AA vs GG      59.8%           0.029     Random         0.38            0.707   0.09    0.930
                                carrier A vs G   63.2%           0.028     Random         0.73            0.462   −0.03   0.978
  **skin cancer**   rs1800629   A vs G           46.1%           0.084     Fixed          0.30            0.764   −0.68   0.528
                                AA vs GG         38.6%           0.148     Fixed          0.38            0.707   0.33    0.756
                                GA vs GG         45.4%           0.089     Fixed          0.30            0.764   −1.36   0.233
                                GA+AA vs GG      46.6%           0.081     Fixed          0.60            0.548   −1.04   0.347
                                AA vs GG+GA      38.1%           0.152     Fixed          0.38            0.707   0.49    0.650
                                carrier A vs G   7.4%            0.372     Fixed          0.30            0.764   −0.95   0.387

SCC: squamous cell carcinoma; SNP: single nucleotide polymorphisms.

For the rs361525 polymorphism and SCC risk, random-effect model was used for the overall SCC, due to the presence of overall significant heterogeneity (Table [6](#T6){ref-type="table"}, all I^2^\>50 %, *P*~heterogeneity~\<0.05). For the rs1800629 polymorphism and the risk of skin cancer, fixed-effect model was used for all models (Table [6](#T6){ref-type="table"}, all I^2^ \< 50 %, *P*~heterogeneity~ \>0.05).

We also performed Begg\'s and Egger\'s tests to evaluate the potential publication bias among the included articles. The results indicate that publication bias can be ruled out for all comparisons (Table [6](#T6){ref-type="table"} and [supplementary Figures 3-4](#SD1){ref-type="supplementary-material"}; all *P*~Begg~\>0.05, *P*~Egger~\>0.05). Moreover, we conducted a sensitivity analysis and confirmed the stability of our results ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"} for rs1800629 and SCC risk; data no shown for others).

DISCUSSION {#s3}
==========

In the present study, 16 case-control studies of *TNF-α* rs1800629 polymorphism \[[@R1], [@R5]--[@R9], [@R14], [@R16]--[@R24]\] and 6 case-control studies of rs361525 polymorphism \[[@R7], [@R8], [@R14], [@R20], [@R21], [@R24]\] were included in the meta-analysis of *TNF-α* polymorphism and the risk of SCC disease. We found that an increased overall SCC risk was associated with the rs1800629 polymorphisms in the Asian population under AA vs GG, and AA vs GG+GA models, but not A vs G, GA vs GG, GA+AA vs GG, or carrier A vs G models. A significant difference between LSCC/OSCC risks and the rs1800629 polymorphism was found under the AA vs GG, and AA vs GG+GA models; this corresponds with previous data on the link of rs1800629 and the risk of upper aero-digestive tract or head/neck SCC \[[@R25], [@R26]\]. However, in 2013, Chen et al performed a meta-analysis to analyze the association between rs1800629 and oral cancer, and observed a negative association between rs1800629 and OSCC \[[@R27]\]. Different selection criteria may contribute to this discrepancy. In our meta-analysis, two studies were excluded due to the requirement of Hardy-Weinberg equilibrium (HWE) or genotype data \[[@R28], [@R29]\]. Regarding the ESCC risk and rs1800629 polymorphism, the negative result was found under all genetic models, which was in line with the data of Luo et al \[[@R30]\]. The rs361525 allele was reported to be significantly increased in healthy controls compared with cancer patients, indicating a protective function \[[@R31]\]. Here, no significant difference was detected for rs361525 and overall SCC risks under all genetic models, which was partly in accordance with the data of Gao et al regarding head and neck SCC \[[@R26]\] and Zhou et al for overall cancer \[[@R32]\]. In addition, seven case-control studies in Caucasian population were included for the analysis of skin cancer \[[@R11]--[@R13], [@R15]--[@R17]\]. We failed to observe a significant association between *TNF-α* rs1800629 and skin cancer. In 2011, Nan et al also did not find any association between *TNF-α* gene variants and skin BCC or SCC in the Genome-Wide Association Studies (GWAS) from 2045 cases and 6013 controls of European population \[[@R33]\].

Although our results were validated by Begg\'s and Egger\'s tests, and by sensitivity analysis, the limitations in our meta-analysis should also be addressed. (1) Due to the limited number of studies published to date, only the common genetic polymorphisms of *TNF-α*, including rs1800629 and rs361525, were chosen. In addition, small sample size and/or limited genotype data in eligible articles affected our analysis. For example, there are two case-control studies of the association between *TNF-α* rs1800629 and melanoma risk \[[@R15], [@R34]\]. However, one study was excluded due to the departure of HWE \[[@R34]\]. The frequency data of GA+AA combined genotype and GG genotype were extracted in one OSCC study \[[@R24]\]. (2) A considerable heterogeneity was observed in the meta-analysis of rs1800629/rs361525 and the SSC risks. SCC has many different etiologies, and stratified analyses by every SCC disease type were not performed. The variations of clinical characteristics, ethnicity, geographical location, habits, gender, age and population feature were not fully considered. In spite of the use of random-effect model, a limited number of studies was included in the subgroup analysis. For example, only one case-control study was included for the rs1800629 and the susceptibility to a specific SCC disease, including SSCC \[[@R16]\] and OPSCC \[[@R21]\]. The subgroup analysis of LSCC and rs361525 was based on only 2 case-control studies \[[@R14], [@R20]\], and showed a positive correlation under A vs G model, GA vs GG model; GA+AA vs GG, and carrier A vs G model. It is possible that the GA genotype of rs361525 is associated with the decreased risk of LSCC. However, well-powered studies and stratified analyses by more factors are required to confirm our findings.

TNF-α is an important multifunctional pro-inflammatory cytokine, which is closely linked to the occurrence, progression, metastasis, prevention and therapy of many types of human cancer \[[@R35]--[@R37]\]. Alterations in *TNF-α* gene expression or TNF-α cytokine release lead to a variety of cancers \[[@R2], [@R38]\]. Genetic variation has been considered as a disease susceptibility or resistance factor \[[@R2]\]. The rs1800629 G/A polymorphism, located in the promoter region (−308 site) of human *TNF-α* gene, can lead to the substitution from G common allele to A rare allele \[[@R2]\]. *In vitro* experiments showed that the "A" rare allele of rs1800629 could increase *TNF-α* transcription \[[@R39], [@R40]\]. The frequency of "A" allele also positively correlates with high TNF-α levels in patients with oral cancer \[[@R28]\]. *TNF-α* rs1800629 was found to be positively associated with distant metastases of triple negative breast cancer patients \[[@R36]\]. However, no association was found between rs1800629 and *TNF-α* gene expression in gastric cancer patients \[[@R41], [@R42]\]. Here, we observed a positive correlation between the AA genotype of rs1800629 and the risks of LSCC/OSCC. However, we did not find any significant association between the A allele and the SCC risks. It is possible that the "A" rare allele functions in an allele dosage-dependent manner. TNF-α was found to increase the efficiency of chemotherapy and radiotherapy against breast cancer cells \[[@R43]\]. The carriage of the A rare allele of rs1800629 may be involved in this process, through inducing TNF-α transcription and protein expression. It may be meaningful to analyze the effect of combined mutations of *TNF-α* and other genes, including TNF-beta and interleukin-6, on the carcinogenesis and SCC cancer therapy, since this may lead to the discovery of potential novel biomarkers for SCC.

In conclusion, our meta-analysis indicates that the AA genotype of *TNF-α* rs1800629 polymorphism may serve as a prognostic biomarker for SCC, especially for LSCC and OSCC in the Asian population. The rs361525 polymorphism does not seem to be a genetic risk factor for SCC. In conjunction with other studies, these results provide a scientific support for the prognostic value of *TNF-α* rs1800629 polymorphisms in predicting the SCC risk.

MATERIALS AND METHODS {#s4}
=====================

Database retrieval {#s4_1}
------------------

The related articles published before January 17^th^, 2017 were searched in the electronic databases, including PUBMED, WOS, EMBASE, WANFANG, CNKI and SCOPUS, without any language restrictions. The present meta-analysis followed "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) \[[@R44]\], as shown in [Supplementary Table 4](#SD2){ref-type="supplementary-material"}.

Article selection {#s4_2}
-----------------

Duplicated articles were removed by EndNote X7 software (Thomson Reuters). The following articles were excluded: 1) Reviews, theses, cases and trials; 2) Meeting abstracts and posters; 3) Cell or animal studies; 4) Other genes or diseases; 5) Meta-analyses; 6) Non-mutation data; 7) Data without detailed genotype; 8) Lack of control data; 9) Studies without specific oral cancer type information; 10) *P* value for HWE (*P*~HWE~) was less than 0.05; 11) Studies with unselected mutation sites. The selected articles provide sufficient information regarding the genotypes for *TNF-α* polymorphisms in case and control groups. *P*~HWE~ values were obtained by the chi-squared test.

Data extraction and quality assessment {#s4_3}
--------------------------------------

The authors extracted independently the following information: First author, publication year, country, ethnicity, number of cases/controls, source of controls, age (mean value), genotyping assay, gender (male %), SNP, genotype frequencies, disease type, χ^2^ and *P*~HWE~ values in control group. Newcastle-Ottawa Scale (NOS) system (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>) was used to assess the quality of the included studies; NOS score ≥7 indicates a high quality study.

Statistical analyses {#s4_4}
--------------------

Mantel-Haenszel statistics was used to estimate the values of pooled odd radios (ORs) and 95 % confidence intervals (CIs); *P*~association~ value less than 0.05 was considered statistically significant. Six genetic models, including allele, homozygote, heterozygote, dominant recessive, or carrier models were used. Cochran Q statistic and I^2^ test were carried out to assess the potential heterogeneities between studies. When *P*~heterogeneity~ value of Cochran Q statistic \> 0.05 or I^2^ value \<50 %, the fixed-effect model was used. Otherwise, random-effect model was applied. To investigate the potential sources of heterogeneity, sensitivity analyses and subgroup analyses based on SCC disease type, ethnicity or source of controls were performed. Begg\'s test with pseudo 95 % confidence limits and Egger\'s test were also conducted to evaluate the potential publication bias. Stata/SE 12.0 (College Station, TX, USA) software was used for all statistical analyses.

SUPPLEMENTARY FIGURES AND TABLES {#s5}
================================

**Authors' contributions**

This study was conceptualized and designed by Ning Liu. Ning Liu, Guang-Jing Liu and Juan Liu extracted and analyzed the data. The manuscript was written by Ning Liu. All authors approved the final manuscript.

**CONFLICTS OF INTEREST**

The authors have declared that no conflicts of interest exists.
